Dallas, Texas 12/11/2013 (FINANCIALSTRENDS) – Access Pharmaceuticals, Inc. (OTCMKTS:ACCP) is one of the leading biopharmaceutical companies that are always focused towards the development of wide range of different products. You can expect them to develop various medical device products which are mainly based on Nano polymer chemistry technologies. Currently the biopharmaceutical company is having one marketed product and there are estimated two different products which are currently a part of phase 2 of the clinical research. Some examples of the products that are being marketed and developed are MuGard, ProLindac, Thiarabine and CobaCyte.
Access Pharmaceuticals, Inc. (OTCMKTS:ACCP) also has different drug delivery platforms that are being used for cancer chemotherapy and are mainly based on Synthetic polymer targeted drug delivery technology. Access Pharmaceuticals got all this technology from the School of Pharmacy, University of London and it further developed a synthetic polymer technology and utilized a unique polymer with platinum. This unique polymer has the ability to exploit permanent and retention effect which targets tumor sites so that the selective accumulation of drug happens and drug release is controlled.
Access Pharmaceutical competitors
There are many other biopharmaceutical companies with which the Access Pharmaceutical competes and some of them are Johnson & Johnson, Endocyte, GlaxoSmithKline, Daiichi, Mersana Therapeutics, Nektar Therapeutics and many other such pharmaceutical companies. The company is also planning to develop some more vaccines and is aggressively trying to expand its research and development program.
The latest program that Access Pharmaceuticals, Inc. (OTCMKTS:ACCP) is undertaking is oral drug delivery that utilizes the body’s natural vitamins such as vitamin B1 and Vitamin B2 for absorption in the intestine with the help of a unique process called as r receptor-mediated endocytosis. Apart from vitamin research the company also wishes to target the tumor related research and is in the process of development of cancer related medicines.